ClinicalTrials.Veeva

Menu
P

Poliklinika Borzan | Osijek, Croatia

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Tulisokibart
MK-7240
MORF-057
MK-7240-001
MK-7240-008
LY4268989
Mirikizumab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 5 total trials

A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease (GARNET)

This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of 3 active dose regimens of M...

Enrolling
Crohn's Disease
Inflammatory Bowel Diseases
Drug: Placebo
Drug: MORF-057

The main purpose of this study is to determine the safety and efficacy of eltrekibart and mirikizumab in adult participants with moderately to severe...

Enrolling
Ulcerative Colitis Chronic
Ulcerative Colitis
Drug: Placebo
Drug: Eltrekibart

The purpose of this protocol is to evaluate the efficacy of tulisokibart in participants with moderately to severely active ulcerative colitis. Study...

Active, not recruiting
Ulcerative Colitis
Drug: IV Placebo
Drug: SC Placebo
Locations recently updated

The purpose of this protocol is to evaluate the efficacy and safety of tulisokibart in participants with moderately to severely active Crohn's diseas...

Enrolling
Crohn's Disease
Other: SC Placebo
Drug: IV Tulisokibart

The main purpose of this study is to evaluate the safety and effectiveness of LY4268989 when compared to placebo in adult participants with moderatel...

Enrolling
Ulcerative Colitis (UC)
Ulcerative Colitis, Active Severe
Drug: Placebo
Drug: LY4268989

Trial sponsors

Lilly logo
Merck Sharp & Dohme (MSD) logo
M

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems